Cardiol Therapeutics Inc.
CRDL
$0.94
$0.011.59%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -48.59% | -2.81% | -13.65% | 40.37% | 101.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -28.71% | -1.93% | -5.80% | 20.92% | 81.64% |
| Operating Income | 28.71% | 1.93% | 5.80% | -20.92% | -81.64% |
| Income Before Tax | 22.48% | -25.36% | 15.19% | -4.08% | -111.08% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 22.48% | -25.36% | 15.19% | -4.08% | -111.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 22.48% | -25.36% | 15.19% | -4.08% | -111.08% |
| EBIT | 28.71% | 1.93% | 5.80% | -20.92% | -81.64% |
| EBITDA | 27.75% | 1.26% | 5.20% | -20.73% | -80.58% |
| EPS Basic | 36.08% | -4.28% | 30.93% | 15.56% | -94.75% |
| Normalized Basic EPS | 36.05% | -4.34% | 30.96% | 15.61% | -95.09% |
| EPS Diluted | 36.08% | -4.28% | 30.93% | 15.56% | -94.75% |
| Normalized Diluted EPS | 36.05% | -4.34% | 30.96% | 15.61% | -95.09% |
| Average Basic Shares Outstanding | 21.31% | 20.22% | 22.82% | 23.39% | 8.30% |
| Average Diluted Shares Outstanding | 21.31% | 20.22% | 22.82% | 23.39% | 8.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |